Upsher-Smith, Roche deal

Upsher-Smith’s Proximagen Ltd. subsidiary granted Roche exclusive, worldwide rights to develop and commercialize an oral small molecule vascular adhesion protein-1 (VAP-1; SSAO) inhibitor that may be effective in treatment of inflammatory diseases. The compound is in Phase II testing. ...